ArticleCancer medicine2023
Multifocal/multicentric breast cancer: Does each focus matter?
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07677956 (Safety Evaluation of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety Evaluation of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer: A Prospective Cohort Study
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Tailoring Escalated Adjuvant Chemotherapy for Multifocal and Multicentric Breast Cancer With Low Tumor Burden.JCO precision oncology · 2026Article
- Invasion dynamics of multifocal breast tumor spheroids in three-dimensional extracellular matrix.Biophysical journal · 2026Article
- Evaluation of the effect of peritumoral surrounding parenchymal features on radiological size measurement in breast cancer patients: a multicenter retrospective study (TR-BRC 2023-01).Japanese journal of radiology · 2026Article
- MRI-derived tumor volume vs. pathological tumor diameter: a comparative study of prognostic value for disease-free survival in multifocal/multicentric breast cancer.Frontiers in oncology · 2026Article
- Clinicopathological characteristics and factors associated with axillary lymph node metastasis in multifocal/multicentric versus unifocal breast cancer: a retrospective study.Frontiers in oncology · 2026Article
- Exploring the recurrence and metastasis of breast invasive ductal carcinoma based on machine learning and survival analysis.Frontiers in oncology · 2026Article
- Clinicopathological characteristics and prognostic analysis of multifocal/multicentric breast cancer.Scientific reports · 2025Article
- Review
- Intertumoral Heterogeneity in Multifocal Breast Cancer Mimicking a Collision Tumor on Imaging: A Case Report.Cureus · 2025Article
- Article
- Great Debate: Does Breast-Conserving Surgery with Radiotherapy Offer Better Survival than Mastectomy in Early-Stage Breast Cancer?Annals of surgical oncology · 2025Article
- Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value.World journal of experimental medicine · 2025Article
- Construction of risk prediction model of sentinel lymph node metastasis in breast cancer patients based on machine learning algorithm.Discover oncology · 2025Article
- Predicting Axillary Lymph Node Metastasis in Young Onset Breast Cancer: A Clinical-Radiomics Nomogram Based on DCE-MRI.Breast cancer (Dove Medical Press) · 2025Article
- Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study.Breast cancer research and treatment · 2024Article
- Multifocal/multicentric breast cancer: Does each focus matter?Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultifocal (MF) and multicentric (MC) breast cancer cases have been increasingly diagnosed owing to the extensive use of improved preoperative breast imaging. The current tumor-node-metastasis staging system uses the dimension of the largest tumor and recommends reporting the pathological features of the largest tumor in MF/MC breast cancers.
aimThis study aimed to explore whether the largest or aggregate dimensions of MF and MC breast cancers can better predict tumor behavior. We also attempted to study the histological and biological heterogeneities of separate foci in MF and MC breast cancers to determine whether it was necessary to examine each lesion.
methodsWe retrospectively analyzed 121 patients with MF/MC (103 with MF and 18 with MC) breast cancers and 484 patients with unifocal breast cancer who were treated at the First Affiliated Hospital of Nanjing Medical University. Two methods were used to record the T stage (using the dimensions of the largest lesion and aggregate dimensions of all lesions). The histological grade, immunohistochemical parameters, and molecular subtypes of the largest lesion and other lesions in MF/MC breast cancers were studied to assess intertumoral heterogeneity.
resultsThe use of aggregate dimensions upstaged 63 patients with MF/MC breast cancers to a more advanced stage and removed the independent effect of cancer multiplicity on lymph node positivity compared with the use of the largest dimension. Mismatches were found in the pathological type (9.9%), histological grade (4.1%), and molecular subtype (8.3%) among different foci.
conclusionThe tendency of MF/MC breast tumors to metastasize may be related to tumor load, which can be better predicted by the aggregate dimensions of all foci. The use of the current staging systems may require further evaluation and modification. Intertumoral heterogeneity indicates the necessity for pathological and immunohistochemical assessments of each lesion in patients with MF/MC breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.